A Phase 3 interventional study of Dupilumab and Matching Placebo in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-20.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2016, is one of 11 in phase 3, and was the 15th registered.
1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 6–17
University of California, San Francisco · Sites in United States
Ages 18+
University of Michigan · Sites in United States
Ages 18+
Sanofi
Ages 18+
By country, each count listing its studies:
dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, dupilumab is the treatment under test here. Read study by study →
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 12 · Phase 4 24
First in 2011; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 75 across the 50 interventional studies. Of the 38 that completed or were terminated, 26 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 50 have an industry lead sponsor. The 10 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals: 1 open now, 2 under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Regeneron Pharmaceuticals, this one is the 9th largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 3, and was the 16th registered.
Regeneron Pharmaceuticals’s Dermatitis, Atopic studies by the year they started, since 2011.
4 of the studies testing dupilumab in Dermatitis, Atopic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07905547SanofiA Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis | 2027-02-07 |
| NCT05983068SanofiA Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis | 2027-04-29 |
| NCT05042258Northwestern UniversityUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis | 2027-06 |
| NCT05268107University of MichiganEthnic Differences in Mechanisms of Action of Dupilumab | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing dupilumab in Dermatitis, Atopic, from their registry updates:
Among Regeneron Pharmaceuticals’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
The main objective of the trial is to evaluate the efficacy of 2 dose regimens of dupilumab compared to placebo, administered with concomitant topical corticosteroids (TCS), in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral Cyclosporine A (CSA), or when this treatment is currently not medically advisable.
The secondary objective is to assess the safety and tolerability of 2 dose regimens of dupilumab compared to placebo, administered with concomitant TCS, in adult patients with severe AD who are not adequately controlled with, or are intolerant to, oral CSA, or when this treatment is currently not medically advisable.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Documented history by a physician of either:
No prior CSA exposure and not currently a candidate for CSA treatment due to:
Previously exposed to CSA, and CSA treatment should not be continued or restarted due to:
Exclusion Criteria:
Treatment with biologics as follows:
Presence of any 1 of the following TB criteria:
NOTE: Any of these 3 TB tests will be performed on a country-by-country basis according to local guidelines only if required by regulatory authorities or ethics boards.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one subcutaneous (SC) injection of dupilumab matching placebo once per week (QW) (following two SC injections on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
Drug: Matching Placebo
Participants received one subcutaneous (SC) injection of dupilumab 300 mg every 2 weeks (Q2W) from Week 1 to Week 15 (following a SC loading dose of 600 mg on day 1). During weeks in which dupilumab was not administered, participants received matching placebo. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
Drug: Dupilumab
Participants received one subcutaneous (SC) injection of dupilumab 300 mg once per week (QW) (following an SC loading dose of 600 mg on day 1) from Week 1 to Week 15. All participants were required to undergo treatment with topical corticosteroids (TCS) using a standardized regimen that continued through the end of the treatment period (Week 16). Starting at week 16, participants could roll over into an open-label extension (OLE) study (R668-AD-1225), if they were considered eligible. Participants who did not enter the OLE study were followed for up to an additional 12 weeks for safety (\[Week 28, end of study (EOS) period\]).
Drug: Dupilumab
Also known as: DUPIXENT®, REGN668, SAR231893
Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the Full Analysis Set (FAS) which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized).
Time frame: Baseline, Week 16
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The analysis population for efficacy analyses is the FAS which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16
The Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16
The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16
Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of participants analyzed" = participants who were evaluable for this endpoint.
Time frame: Baseline to Week 16
Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).
Time frame: Baseline, Week 16
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score is indicative of a poor QOL. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period
The type, amount, frequency, and potency of topical products used during the study were recorded at home by participants in a medication diary. Participants returned TCS tubes at each clinic visit up until week 16, and these tubes were weighed by the site staff to determine the actual amount of TCS used. During the 16-week placebo-controlled study treatment period, medium-potency TCS dosing frequency was symptom-based (IGA score) adjusted every 4 weeks per the protocol-specified tapering algorithm. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number Analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline to week 16
Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16
The HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3, for possible scores ranging from 0 (no symptoms) to 21 (severe symptoms) for each of the anxiety and depression subscales. Recommended cut-off scores for both subscales to identify psychiatric distress are: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Scores less than 7 do not indicate psychiatric distress. Total score is the sum of the two sub-scores.
Time frame: Baseline, Week 16
Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16
The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).
Time frame: Baseline, Week 16
Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification)
Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Full Analysis Set (FAS) included all randomized. Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 16
Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2
Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.
Time frame: Baseline, Week 2
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Safety analysis set (SAF) included all randomized participants who received any study drug; it was based on the treatment received (as treated).
Time frame: Baseline to Week 16
Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
Time frame: Baseline to Week 16
Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
Time frame: Baseline to Week 16
Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
Time frame: Baseline to Week 16
The study was conducted at 73 sites in Europe. A total of 390 participants were screened between 28 Jan 2016 and 14 Sep 2016. Of those, 325 participants were enrolled into the study and randomized. Sixty participants were considered screen failures, mostly due to unmet eligibility criteria.
| Milestone | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Started | 108 | 107 | 110 |
| Completed treatment (week 16) | 107 | 106 | 109 |
| Completed study (week 28) | 7 | 8 | 8 |
| Completed | 7 | 8 | 8 |
| Not completed | 101 | 99 | 102 |
| Withdrew: Transitioned into ole study | 99 | 98 | 100 |
| Withdrew: Did not complete follow-up visits | 1 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
| Withdrew: Undecided | 1 | 0 | 0 |
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the Full Analysis Set (FAS) which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized).
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Eczema Area and Severity Index (EASI) 75 (≥75% Improvement From Baseline) at Week 16 | 29.6 | 62.6 | 59.1 |
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. The analysis population for efficacy analyses is the FAS which included all randomized participants. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.
| Percent Change | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16 | -46.6 ± 2.76 | -79.8 ± 2.59 | -78.2 ± 2.55 |
The Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
| Percent Change | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) at Week 16 | -25.4 ± 3.39 | -53.9 ± 3.14 | -51.7 ± 3.09 |
The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.
| Percent Change | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16 | -29.5 ± 2.55 | -62.4 ± 2.48 | -58.3 ± 2.45 |
Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of participants analyzed" = participants who were evaluable for this endpoint.
| Percentage of participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus NRS From Baseline to Week 16 | 14.3 | 45.7 | 40.4 |
BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "number of participants analyzed" = participants who were evaluable for this endpoint.
| Percent BSA | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Change From Baseline in Percent Body Surface Area (BSA) Involvement With Atopic Dermatitis (AD) at Week 16 | -19.57 ± 1.798 | -39.23 ± 1.715 | -37.52 ± 1.690 |
IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5 point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Investigator Global Assessment (IGA) 0 or 1 (on the 0 to 4 IGA Scale) and a Reduction From Baseline of ≥2 Points at Week 16 | 13.9 | 40.2 | 39.1 |
The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score is indicative of a poor QOL. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
| Score on a Scale | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -4.5 ± 0.49 | -9.5 ± 0.46 | -8.8 ± 0.45 |
The POEM is a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = participants who were evaluable for this endpoint.
| Score on a Scale | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Change From Baseline in the Patient Oriented Eczema Measure (POEM) at Week 16 | -4.3 ± 0.62 | -11.9 ± 0.60 | -11.4 ± 0.59 |
The EASI score is used to measure the severity and extent of atopic dermatitis (AD) and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Eczema Area and Severity Index (EASI) Score (≥75% Improvement From Baseline) at Week 16 for Participants With Prior CSA Use | 26.4 | 58.0 | 56.5 |
The type, amount, frequency, and potency of topical products used during the study were recorded at home by participants in a medication diary. Participants returned TCS tubes at each clinic visit up until week 16, and these tubes were weighed by the site staff to determine the actual amount of TCS used. During the 16-week placebo-controlled study treatment period, medium-potency TCS dosing frequency was symptom-based (IGA score) adjusted every 4 weeks per the protocol-specified tapering algorithm. The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number Analyzed" = Participants who were evaluable for this endpoint.
| Grams | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Change From Baseline in Mean Weekly Dose of Topical Corticosteroid (TCS) Use During Treatment Period | 25.1 ± 1.48 | 15.0 ± 1.51 | 17.5 ± 1.49 |
The HADS is a 14-item scale, with 7 items relating to anxiety and 7 relating to depression. Each item on the questionnaire is scored from 0-3, for possible scores ranging from 0 (no symptoms) to 21 (severe symptoms) for each of the anxiety and depression subscales. Recommended cut-off scores for both subscales to identify psychiatric distress are: 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression. Scores less than 7 do not indicate psychiatric distress. Total score is the sum of the two sub-scores.
| Score on a Scale | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Change From Baseline in Total Hospital Anxiety and Depression Scale (HADS) Score at Week 16 | -2.3 ± 0.56 | -6.1 ± 0.54 | -5.2 ± 0.53 |
The SCORAD is a clinical tool for assessing the severity of AD. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized).
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants Achieving SCORAD 50 (≥50% Improvement From Baseline) at Week 16 | 25.9 | 66.4 | 55.5 |
Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Full Analysis Set (FAS) included all randomized. Here "Number of Participants Analyzed" = Participants who were evaluable for this endpoint.
| Percent Change | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percent Change From Baseline in the Total Global Individual Signs Score (GISS) at Week 16 (Erythema, Infiltration/ Papulation, Excoriations, Lichenification) | -29.0 ± 2.75 | -55.2 ± 2.66 | -53.3 ± 2.65 |
Pruritus NRS is an assessment tool used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would you rate your itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). The analysis population for efficacy analyses is the FAS. Efficacy analyses were based on the treatment allocated (as randomized). Here "Number of Participants analyzed" = Participants who were evaluable for this endpoint.
| Percent Change | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percent Change From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (NRS) Score at Week 2 | -10.0 ± 2.24 | -17.2 ± 2.25 | -19.7 ± 2.21 |
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. Safety analysis set (SAF) included all randomized participants who received any study drug; it was based on the treatment received (as treated).
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Treatment Period | 8.3 | 1.9 | 3.6 |
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
| Percentage of Participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants Having at Least One Serious Treatment Emergent Adverse Event (TEAE) Through Treatment Period | 1.9 | 1.9 | 1.8 |
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
| Percentage of participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants Having at Least One Treatment-Emergent Adverse Event (TEAE) Leading to Treatment Discontinuation Through Treatment Period | 0.9 | 0 | 1.8 |
Treatment-emergent adverse events (TEAEs) were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug to the last study dose (Week 16). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. SAF included all randomized participants who received any study drug; it was based on the treatment received (as treated).
| Percentage of participants | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Percentage of Participants With Treatment-Emergent Adverse Events Through Treatment Period | 69.4 | 72.0 | 69.1 |
Collected over All Adverse Events (AEs) were collected from signature of informed consent form up to end of study (EOS), Week 28, regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo QW + TCS | 0/108 (0%) | 2/108 (1.9%) | 45/108 (41.7%) |
| Dupilumab 300 mg Q2W + TCS | 0/107 (0%) | 2/107 (1.9%) | 54/107 (50.5%) |
| Dupilumab 300 mg QW + TCS | 0/110 (0%) | 3/110 (2.7%) | 51/110 (46.4%) |
| Event | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| Pancreatitis acuteGastrointestinal disorders | 0/108 | 1/107 | 0/110 |
| HepatotoxicityHepatobiliary disorders | 0/108 | 1/107 | 0/110 |
| HemiparesisNervous system disorders | 1/108 | 0/107 | 0/110 |
| EmphysemaRespiratory, thoracic and mediastinal disorders | 1/108 | 0/107 | 0/110 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/108 | 0/107 | 1/110 |
| UreterolithiasisRenal and urinary disorders | 0/108 | 0/107 | 1/110 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 0/108 | 0/107 | 1/110 |
| Event | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/108 | 22/107 | 18/110 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 18/108 | 8/107 | 10/110 |
| Conjunctivitis allergicEye disorders | 7/108 | 16/107 | 10/110 |
| ConjunctivitisInfections and infestations | 4/108 | 12/107 | 8/110 |
| HeadacheNervous system disorders | 10/108 | 10/107 | 11/110 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 1/108 | 7/107 | 4/110 |
| Age, Continuous(years) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 38.9 ± 13.35 | 37.5 ± 12.89 | 38.7 ± 13.21 | 38.4 ± 13.13 |
| Sex: Female, Male(Participants) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Female | 40 | 42 | 44 | 126 |
| Male | 68 | 65 | 66 | 199 |
| Eczema Area and Severity Index (EASI) Score(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 32.9 ± 10.80 | 33.3 ± 9.93 | 33.1 ± 11.02 | 33.1 ± 10.56 |
| Peak Weekly Averaged Pruritus Numerical Rating Scale (NRS) score(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 6.4 ± 2.23 | 6.6 ± 2.10 | 6.2 ± 2.01 | 6.4 ± 2.11 |
| Body Surface Area (BSA) Involvement of Atopic Dermatitis(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 55.0 ± 20.51 | 56.1 ± 17.83 | 56.0 ± 19.26 | 55.7 ± 19.18 |
| Global Individual Signs Score (GISS)(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 9.4 ± 1.63 | 9.3 ± 1.64 | 9.1 ± 1.63 | 9.3 ± 1.64 |
| Dermatology Life Quality Index (DLQI) Total Score(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 13.2 ± 7.60 | 14.5 ± 7.63 | 13.8 ± 8.03 | 13.8 ± 7.75 |
| Patient Oriented Eczema Measure (POEM)(Score on a Scale) | Placebo QW + TCS | Dupilumab 300 mg Q2W + TCS | Dupilumab 300 mg QW + TCS | Total |
|---|---|---|---|---|
| Mean | 19.1 ± 5.99 | 19.3 ± 6.21 | 18.6 ± 6.97 | 19.0 ± 6.40 |
5 further baseline measures are reported on the registry.
Ran from Jan 2016 to primary completion in Jan 2017, 11 months.
Results were first posted in Aug 2020, 3 years 7 months after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 11 months is below that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dupilumab